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Background: Preoperative chemoradiotherapy (CRT) is the cornerstone of treatment for locally advanced rectal
cancer (LARC). Although high local control is achieved, overall rates of distant control remain suboptimal. Colorectal
carcinogenesis is associated with critical alterations of the Wnt/β-catenin pathway involved in proliferation and
survival. The aim of this study was to assess whether CRT induces changes in the expression of β-catenin/E-cadherin,
and to determine whether these changes are associated with survival.
Methods: The Immunohistochemical expression of nuclear β-catenin and membranous E-cadherin was prospectively
analysed in tumour blocks from 98 stage II/III rectal cancer patients treated with preoperative CRT. Tumour samples
were collected before and after CRT treatment. All patients were treated with pelvic RT (46–50 Gy in 2 Gy fractions) and
5-fluorouracil (5FU) intravenous infusion (225 mg/m2) or capecitabine (825 mg/m2) during RT treatment, followed by
total mesorectal excision (TME). Disease-free survival (DFS) was analysed using the Kaplan-Meier method and a
multivariate Cox regression model was employed for the Multivariate analysis.
Results: CRT induced significant changes in the expression of nuclear β-catenin (49% of patients presented an
increased expression after CRT, 17% a decreased expression and 34% no changes; p = 0.001). After a median
follow-up of 25 months, patients that overexpressed nuclear β-catenin after CRT showed poor survival compared
with patients that experienced a decrease in nuclear β-catenin expression (3-year DFS 92% vs. 43%, HR 0.17; 95%
CI 0.03 to 0.8; p = 0.02). In the multivariate analysis for DFS, increased nuclear β-catenin expression after CRT almost
reached the cut-off for significance (p = 0.06).
Conclusions: In our study, preoperative CRT for LARC induced significant changes in nuclear β-catenin expression,
which had a major impact on survival. Finding a way to decrease CRT resistance would significantly improve LARC
patient survival.
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Preoperative chemoradiotherapy (CRT) is the standard
treatment for locally advanced rectal cancer (LARC).
However, although high local control is achieved with
multi-modality treatment, overall rates of distant control
remain suboptimal in 30% of patients, and it is considered
the leading cause of treatment failure [1].* Correspondence: jaimegomezmillan@gmail.com
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distribution, and reproduction in any mediumNowadays, molecular pathways of tumour resistance
in rectal cancer are not fully understood and research fo-
cused on these mechanisms is urgently needed to improve
patient survival. Colorectal carcinogenesis is associated
with critical alterations of the Wnt/β-catenin signalling
pathway [2]. β-catenin is a key multifunctional adaptor
protein harbouring functions that are related to the
subcellular location [3]. In the cytoplasm and within the
membrane, β-catenin binds to intracellular E-cadherin and
plays a role in cell adhesion and maintenance of normal
cellular architecture. In the nucleus, β-catenin associatesentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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factors and activates the expression of target genes that
enhance proliferation and cell survival. β-catenin is con-
trolled by a multi-protein degradation complex, which con-
tains the tumour suppressor adenomatous polyposis coli
(APC), Axin, glycogen synthase kinase 3β (GSK3β) and
casein kinase I [2,4].
Mutations occur in APC as an early event in the car-
cinogenesis of colorectal cancer, which results in an accu-
mulation of β-catenin in the cytoplasm and translocation
of β-catenin to the nucleus. Nuclear β-catenin binds to
transcription factors of the high-mobility-group (HMG)
box TCF/LEF family and results in enhanced proliferation
and survival. β-catenin forms an adherens complex with
E-cadherin, which is regulated by tyrosine phosphorylation
[5] and which dissociates β-catenin from the complex and
causes the release of β-catenin into the cytoplasm [6].
The association between the expression of nuclear β-
catenin and patient survival has been previously described;
however, the conclusions vary dramatically. Lugli et al.
studied more than 1000 colorectal tumours initially treated
with surgery, showing that an increase in nuclear β-catenin
and a loss of membranous E-cadherin expression were
independent prognostic factors for poor survival [7]. How-
ever, other reports have shown that increased nuclear
β-catenin confers an advantage in survival [8].
Radiation has been shown to induce different molecular
changes in both cellular RNA and proteins, resulting in
increased proliferation, migration and cell cancer inva-
siveness. These effects counteract cell death, rendering
the tumour more aggressive and decreasing the efficacy
of radiation [9]. Some studies relate radiation resistance
and the Wnt/β-catenin pathway. A recent study with
pancreatic tumour xenografts has shown that radiation
might induce radiation resistance through the phosphoryl-
ation and inhibition of GS3KB and the subsequent trans-
location of β-catenin to the nucleus [10]. Despite these
preclinical results, the induction of changes in nuclear
β-catenin and E-cadherin expression after RT or CRT and
the implications for prognosis remain undetermined in
the clinical setting.
In the present study, we aimed to prospectively evalu-
ate changes in the expression profile of β-catenin and
E-cadherin after CRT and the impact on survival in LARC
patients treated with combined RT and 5-fluorouracil
based CT.
Methods
Patient data and eligibility
Between January 2008 and December 2010, 98 patients
with stage II-III (T2-T4 and/or N1-N2) rectal adeno-
carcinoma who were candidates for preoperative RT
combined with CT were prospectively recruited in two
centres.Pretreatment evaluation included a complete history and
physical examination with a digital rectal examination,
colonoscopy with biopsy, abdomen and pelvic scan, chest
X-ray, and magnetic resonance image (MRI) of the pelvis.
Additionally, in 40% of patients, an endorectal ultrasound
was performed. All patients were treated according to
the routine protocol with pelvic RT (46–50 Gy in 2 Gy
fractions) and 5-fluorouracil (5FU) intravenous infusion
(225 mg/m2) or capecitabine (825 mg/m2) during RT treat-
ment, followed by total mesorectal excision (TME) 6 weeks
after CRT treatment. Local response to CRT was patho-
logically staged using criteria described by Mandard et al.
[11] based on tumour regression grade (TRG) as follows:
grade 1: tumour with fibrosis without tumour cells; grade
2: predominant fibrosis with scarce tumour cells; grade 3:
fibrosis with tumour cells inside; grade 4: tumour cells
outside of the fibrotic area; and grade 5: no tumour cells.
Due to the low number of patients enrolled in the study,
TRG was divided into two groups: group 1 comprised
TRG 1–2 (good response) while group 2 comprised pa-
tients with regression grades 3–5 (poor response). Regional
response was measured according to the presence or ab-
sence of tumour cells in the lymph nodes of the surgical
specimen. After surgery, patients were treated with adju-
vant chemotherapy (5-FU: 4 cycles of 500 mg/m2 once a
day for 5 days repeated every 21 days, or capecitabine:
4 cycles of 1250 mg/m2 every 12 h for 14 days).
After treatment, all patients underwent clinical exami-
nations and imaging on a regular basis. Patients were
assessed for the occurrence of local, distant relapse, and
death.
β-catenin and E-cadherin immunostaining
Tumour samples were collected during diagnosis (pre-CRT)
and during surgery (post-CRT). Samples were embedded
in paraffin for immunohistochemistry (IHC) and serial
cross-sections of each tumour sample were cut and stained
with hematoxylin and eosin (H&E). β-catenin and E-
cadherin IHC was performed on formalin-fixed, paraffin-
embedded (FFPE) tissue. For the qualitative detection of
β-catenin (rat monoclonal antibody clone βcatenin-1) and
E-cadherin (rat monoclonal antibody clone NCH-38) a
Dako Autostainer (Dako, Copenhagen, Denmark) was
used. E-cadherin and nuclear β-catenin were examined
by staining consecutive sections of each sample.
To study the expression of these proteins before CRT,
a number of endoscopic biopsies ranging between 5 and
10 per tumour were fixed in formalin and embedded in
paraffin. To investigate the expression after CRT, different
paraffin blocks were obtained. After H&E staining, the
block with the most representative part of the tumour was
selected. Thus, in every section, the central and peripheral
parts of the tumour were considered in order to measure
the protein expressions. Two colon cancer sections known
Figure 2 Rectal cancer specimen showing tumour cells with
absence of membrane staining for E-cadherin.
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tive controls, and omission of primary antibody was used
as the negative control. The expression of β-catenin and
E-cadherin were semi-quantitatively evaluated independ-
ently by two different pathologists without knowledge of
the clinical and pathological parameters of the patients.
β-catenin expression in the nucleus was evaluated, and
the percentage of tumour cells that expressed β-catenin
was determined. We calculated the ratio between the
number of tumour cells that expressed β-catenin and
the whole number of tumour cells in the tissue section,
before and after CRT (Figure 1). The expression was
categorised as follows: absent (0% of cells); low (less
than 25% of cells); moderate (between 25% and 75% of
cells) or high (more than 75% of cells). For analytical pur-
poses, the variable was dichotomised as low β-catenin
expression (less than 25% of cells) and high β-catenin
expression (25-100%) [12].
E-cadherin expression in the membrane was evaluated
based on the percentage of tumour cells that expressed
E-cadherin (Figure 2). The expression was categorised as
follows: absence (no expression); low (less than 25% of
cells); moderate (between 25% and 75% of cells) or high
(more than 75% of cells). E-cadherin expression was
dichotomised based on absence (no expression) or pres-
ence (low, moderate and high expression) [7].
To ascertain the tumours that presented changes in
the expression of β-catenin, we compared the expression
levels of β-catenin before and after CRT. Changes in
expression were categorised as follows: increase (fromFigure 1 Tumour cells showing different staining percentages for nuc
nuclear staining. (B): low expression (less than 25% of cells). (C): moderate
(more than 75% of cells).lack of expression to any other category, from low to mod-
erate or high, and from moderate to high); decrease (from
high to any category, from moderate to low or absence,
and from low to absence); or equal (no change in cat-
egory). To assess the differential expression of E-cadherin
between pre-CRT and post-CRT samples, changes were
categorised as follows: increase (from absence to any other
category, from low to moderate, high, or no loss, and from
moderate to high or no loss); decrease (from no loss to
any other category, from high to moderate or low or
absence, from moderate to low or absence and from low
to absence) or equal (no change of category).lear betacatenin. (A): Rectal cancer specimen showing absence of
expression (between 25% and 75% of cells). (D): High expression
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Patients, type of treatment and disease characteristics were
tabulated by means of frequency tables. Qualitative vari-
ables are expressed as a percentage with a 95 confidence
interval of the percentage, and quantitative variables are
expressed as the median and range. The association be-
tween qualitative dichotomised data of protein expression
and clinico-pathological prognostic factors were compared
using the chi-square test and Fisher’s exact test when
appropriate. The Wilcoxon paired test was used for paired
samples to compare pre-CRT and post-CRT protein ex-
pression levels. The end points of interest were tumour
relapse and disease-free survival (DFS). DFS was defined
as the time from first treatment to first documented relapse,
secondary tumour or death by any cause. To investigate the
pattern of occurrence over time of any of the aforemen-
tioned end points, descriptive analyses were carried out by
estimating Kaplan-Meier survival curves, whereas inferen-
tial analyses relied on cumulative hazards. The threshold
for significance for two-sided analysis was set to p > 0.05.
Multivariate survival analysis was conducted using aTable 1 Clinico-pathological data and distribution of scores in
E-cadherin
Factors N (%) 98 (100) Absent Low Mode-rate
Sex
M 72 (73%) 1 (1%) 2 (3%) 13 (18%)
F 26 (27%) 1 (4%) 0 (0%) 5 (19%)
Age
</= 50 48 (49%) 2 (2%) 1 (1%) 15 (18%)
>50 50 (51%) 0 (0%) 1 (7%) 3 (21%)
Anal margin
<= 5 cm 84 (86%) 1 (2%) 1 (2%) 7 (15%)
>5 cm 4 (14%) 1 (2%) 1 (2%) 11 (22%)
T stage
T2-3 80 (82%) 2 (3%) 2 (3%) 15 (19%)
T4 18 (18%) 0 (0%) 0 (0%) 3 (17%)
N stage
N- 43 (44%) 0 (0%) 1 (2%) 7 (13%)
N+ 55 (56%) 2 (4%) 1 (2%) 11 (24%)
TGR*
TGR 1 17 (17%) 0 (0%) 1 (6%) 3 (18%)
TGR 2 27 (28%) 1 (4%) 0 (0%) 3 (11%)
TGR 3 23 (24%) 1 (4%) 1 (4%) 2 (9%)
TGR 4 26 (26%) 0 (0%) 0 (0%) 8 (31%)
TGR 5 5 (5%) 0 (0%) 0 (0%) 2 (40%)
pN ††
pN- 70 (71%) 2 (3%) 1 (1%) 13 (19%)
pN+ 28 (29%) 0 (0%) 1 (4%) 5 (18%)
*TGR: Tumor grade regression. †† pN: pathological lymphatic metastases.multivariate Cox regression model. P values below the con-
ventional 5% threshold were regarded as significant. All of
the analyses were conducted using R and SPSS (Statistical
Package for the Social Sciences) version 15.0 software.
Ethics statement
This study was carried out in compliance with the Declar-
ation of Helsinki (http://www.wma.net/en/30publications/
10policies/b3/index.html). All subjects provided informed
consent for study inclusion, and the study was approved
by our hospitals’ Ethics Committees (Comité de Etica of
Hospital Virgen de la Victoria, Málaga, Spain; Comité de
Etica of Hospital Juan Ramón Jiménez, Huelva, Spain).
Results
Clinico-pathologic characteristics of the patients
Of the 98 patients included, the vast majority were male,
T3, with clinical lymph nodal metastasis and a distance ≤
5 cm to anal verge. Tumours received a mean dose of RT
of 47.9 Gy (range 46–50). After CRT, 44 patients (45%)
presented a TRG 1–2, and 54 patients (55%) a TRG 3–5.the entire cohort of patients
Nuclear β-catenin
High Absent Low Mode-rate High
56 (78%) 30 (42%) 26 (36%) 12 (17%) 4 (6%)
20 (77%) 9 (35%) 9 (35%) 6 (23%) 2 (8%)
66 (77%) 33 (39%) 31 (37%) 15 (18%) 5 (6%)
10 (72%) 6 (43%) 4 (29%) 3 (21%) 1 (7%)
39 (81%) 21 (44%) 17 (35%) 7 (15%) 3 (6%)
37 (72%) 18 (36%) 18 (36%) 11 (22%) 3 (6%)
61 (85%) 29 (36%) 30 (37%) 15 (19%) 6 (8%)
15 (83%) 10 (56%) 5 (28%) 3 (17%) 0 (0%)
44 (85%) 21 (40%) 16 (31%) 12 (23%) 3 (6%)
32 (70%) 18 (39%) 19 (41%) 6 (13%) 3 (7%)
13 (76%) 5 (29%) 9 (53%) 2 (12%) 1 (6%)
23 (85%) 7 (26%) 11 (41%) 7 (26%) 2 (7%)
19 (83%) 11 (48%) 6 (26%) 4 (17%) 2 (9%)
18 (69%) 14 (54%) 7 (27%) 4 (15%) 1 (4%)
3 (60%) 8 (40%) 2 (40%) 1 (20%) 0 (0%)
54 (77%) 27 (39%) 26 (37%) 12 (17%) 5 (7%)
22 (78%) 12 (43%) 9 (32%) 6 (21%) 1 (4%)
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lymph node metastases compared with 55 patients (56%)
of lymph node metastases detected by imaging tests before
CRT (P < 0.05). Table 1 describes the clinico-pathological
data and distribution of the scores in the entire cohort of
patients. A significant association was observed between
the presence of a TRG 1–2 and the absence of lymph node
metastasis in the surgical specimen (p = 0.01). Twenty-four
patients (24%) presented a high expression of nuclear
β-catenin (18 moderate and 6 high) and 46 patients
(47%) presented an absence of E-cadherin expression in
the membrane. There was neither an association between
the absence of E-cadherin in the membrane and the ex-
pression of nuclear β-catenin (p = 0.4), nor significant asso-
ciations between nuclear β-catenin or E-cadherin expression
and clinico-pathological characteristics (Table 2).
CRT induces changes in the expression of nuclear β-catenin
Of the 98 patients initially included in the study, a total
of 69 were fully assessable in terms of availability of the
tumoral specimen pre- and post-CRT. Twenty-nine pa-
tients were excluded from the analysis for several reasons:Table 2 Distribution of nuclear β-catenin and E-cadherin relat
Prognostic factors All patients E-cadherin
Absence vs. prese
N % N % N
98 100 46 47% 52
Sex
Male 72 73% 33 46% 39
Female 26 27% 13 50% 13
Age
</= 50 48 49% 9 64% 36%
>50 50 51% 37 44% 47
Distance to anal margin
</= 5 cm 84 86% 22 46% 26
>5 cm 14 14% 24 48% 26
T stage
T2-3 82 83% 38 47% 42
T4 17 17% 8 44% 10
N stage
N- 43 44% 19 43% 25
N+ 55 56% 27 50% 37
TGR*
TGR 1-2 44 45% 18 41% 26
TGR 3-5 54 55% 28 52% 26
pN ††
pN- 70 71% 20 74% 7
pN+ 28 29% 54 76% 17
*TGR: Tumor grade regression. †† pN: pathological lymphatic metastases.17 patients presented a complete response (TRG 1), and
12 patients harboured only a few residual tumour cells
that could not be assessed for IHC (5 patients with TRG 2
and 7 patients with unknown TRG). Clinico-pathological
data of the 69 patients and distribution of the scores are
described in Table 3.
Preoperative CRT significantly increased nuclear β-
catenin expression (49% of patients presented increased
expression after CRT, 17% decreased expression and 34%
no change; p = 0.001). No significant changes in the expres-
sion of E-cadherin were observed after preoperative treat-
ment (Table 4).
Recurrences
Among the 98 patients included in the initial cohort of
the study, with a median follow-up time of 25 months
(range 5–58), we observed 22 recurrences (23%): 6 (6%)
locoregional failures and 16 (16%) distant failures (13 dis-
tant failures and 3 patients with distant and locoregional
failure). No significant association was found between
disease recurrence and nuclear β-catenin or E-cadherin




nce Absence vs. presence
% N % N %
53% 74 76% 24 24
54%
P=0.4
56 78% 16 22%
P=0.4
50% 18 69% 8 31%
P=0.95
P=0.6
10 71% 4 29%
56% 64 76% 20 24%
P=0.754%
P=0.8
38 79% 10 21%
52% 36 72% 14 28%
P=0.453%
P=0.8
59 74% 21 26%
56% 15 83% 3 17%
P=0.257%
P=0.5
19 43% 25 57%
50% 22 41% 32 59%
P=0.659% P=0.2 32 73% 12 27%
48% 42 78% 12 22%
P=0.8 P=0.926% 30 44% 41 56%
24% 11 41% 16 59%
Table 3 Clinico-pathological data and distribution of scores in the entire cohort of patients with pre- and post-CRT
available specimens
E-cadherin Nuclear β-catenin
Factors N (%) 69 (100) Absent Low Mode-rate High Absent Low Mode-rate High
Sex
M 50 (73%) 1 (2%) 1 (2%) 7 (14%) 41 (82%) 24 (48%) 14 (28%) 3 (16%) 3 (6%)
F 19 (27%) 1 (5%) 0 (0%) 4 (21%) 14 (74%) 9 (47%) 7 (37%) 9 (18%) 0 (0%)
Age
</= 50 8 (12%) 0 (0%) 0 (0%) 2 (25%) 6 (75%) 4 (50%) 2 (25%) 1 (12%) 1 (13%)
>50 61 (88%) 2 (3%) 1 (2%) 9 (15%) 13 (21%) 29 (47%) 19 (31%) 11 (18%) 2 (3%)
Anal margin
<= 5 cm 34 (49%) 1 (3%) 1 (3%) 5 (15%) 27 (79%) 18 (53%) 8 (23%) 5 (15%) 3 (9%)
>5 cm 35 (51%) 1 (3%) 0 (0%) 6 (17%) 28 (80%) 15 (43%) 13 (37%) 7 (20%) 0 (0%)
T stage
T2-3 54 (79%) 2 (4%) 1 (2%) 8 (15%) 33 (80%) 24 (44%) 17 (32%) 10 (18%) 3 (6%)
T4 15 (22%) 0 (0%) 0 (0%) 3 (20%) 12 (80%) 9 (60%) 4 (27%) 2 (13%) 0 (0%)
N stage
N- 37 (54%) 0 (0%) 1 (3%) 5 (13%) 31 (84%) 18 (49%) 9 (24%) 8 (22%) 2 (5%)
N+ 32 (46%) 2 (6%) 0 (0%) 6 (20%) 24 (75%) 15 (47%) 12 (37%) 4 (13%) 1 (3%)
TGR *
TGR 2 20 (29%) 1 (5%) 0 (0%) 2 (10%) 17 (85%) 7 (35%) 7 (35%) 5 (25%) 1 (5%)
TGR 3 20 (29%) 1 (5%) 1 (5%) 1 (5%) 17 (85%) 11 (55%) 5 (25%) 3 (15%) 1 (5%)
TGR 4 24 (26%) 0 (0%) 0 (0%) 6 (25%) 18 (75%) 13 (54%) 7 (29%) 3 (13%) 1 (4%)
TGR 5 5 (7%) 0 (0%) 0 (0%) 2 (40%) 3 (60%) 2 (40%) 2 (40%) 1 (20%) 0 (0%)
pN ††
pN- 46 (67%) 0 (0%) 1 (4%) 2 (9%) 20 (87%) 22 (48%) 14 (30%) 8 (17%) 2 (4%)
pN+ 23 (33%) 2 (4%) 0 (0%) 9 (20%) 35 (66%) 11 (49%) 7 (30%) 4 (17 %) 1 (4%)
* TGR: Tumor grade regression. †† pN: pathological lymphatic metastases.
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with the increase or decrease of nuclear β-catenin expres-
sion after CRT. Of the 69 patients included, we observed
20 recurrences (29%): 5 (7%) locoregional failures and 15
(22%) distant failures (13 distant failures and 2 distant and
locoregional failures). Interestingly, of the 20 patients with
recurrent disease and available tumoral sample, 19 (95%)
presented an increased nuclear expression after CRT. 100%
of patients with metastatic disease presented an increase in
nuclear β-catenin expression after CRT. On the other hand,
considering all the patients that presented a decrease in the
expression of nuclear β-catenin after CRT, 92% were free
of disease at 3 years (p = 0.03).Survival
Effect of β-catenin and E-cadherin expression at diagnosis
on patient survival
Of 98 patients initially included, with a median follow
up of 25 months (range 5 to 58 months), 13 patients had
died: 6 (46%) because of primary cancer and 7 (54%) forother causes. The 3-year OS and DFS rates were 90% and
78%, respectively.
No differences in survival were observed in patients
with high nuclear β-catenin compared with those with low
nuclear β-catenin (3 year DFS: 71% vs. 52%; HR = 0.93; 95%
CI 0.37 to 2.4; p = .0.9) (Figure 3). Moreover, no survival
differences were observed in patients with presence of
E-cadherin compared with those with absence (3 year
DFS: 71% vs. 52%; HR = 0.58; 95% CI 0.23 to 1.45; p = .0.2)
(Figure 3).Effects of changes of β-catenin and E-cadherin after RT-CT
on survival
To study the effects of changes in β-catenin and E-
cadherin expression on survival, we analysed the cohort
of 69 patients with available samples pre- and post-CRT
to consider whether an increased, decreased or equal
expression of β-catenin and E-cadherin after CRT were
associated with differences in disease-free survival rates.
After preoperative CRT, changes in the expression of




PRE RT-CT POST RT-CT
PPatients Patients
N (69) % N (69) %
Nuclear β-catenin score
P=0.001
Absent 33 48% 23 33%
Low 21 30% 19 28%
Moderate 12 17% 15 22%
High 3 4% 12 17%
Membranous E-cadherin score
P=0.13
Absent 2 3% 5 7%
Low 1 1% 1 1%
Moderate 11 16% 8 12%
High 16 23% 24 35%
Very high 39 57% 31 50%
β-catenin. Absent: Absence of cells expressing β-catenin; Low: Less than 25%
of cells; Moderate: Between 25% and 75% of cells; High: More than 75% of
cells. E-cadherin. Absent: Absence of cells expressing E-cadherin. Low: Less of
25% of cells expressing E-cadherin. Moderate: Between 25% and 75% of cells
expressing E-cadherin. High: More than 75% of cells expressing E-cadherin.
Very high: 100% of cells expressing E-cadherin.
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rates. Patients with an increase in the number of cells
that expressed nuclear β-catenin after CRT showed poor
survival compared with patients who experienced a de-
crease (3-year DFS 92% vs. 43%, HR 0.17; 95% CI 0.03
to 0.8; p = 0.02) (Figure 4). However, patients with an in-
crease in the number of cells with absence of expression
of E-cadherin did not show a significant difference in
survival (3-year DFS 69% vs. 27%, HR 1.8; 95% CI 0.8 to
4.7), compared with patients who experienced a decreaseFigure 3 Kaplan-Meier estimates of disease-free survival according to
B. Data on disease-free survival (DFS) for the entire group are shown accor
membranous E-cadherin expression.(Figure 4). In the Cox regression analysis with DFS as end
point, when adjusting for N category, TRG and nuclear
β-catenin expression, postoperative lymph node metasta-
ses and T stage were the only prognostic factors independ-
ently associated with a poor prognosis in the multivariate
analysis. Increased nuclear β-catenin expression after
CRT almost reached the cut-off for significance (p = 0.06)
(Table 5).
Discussion
Colorectal carcinogenesis is associated with critical alter-
ations of the Wnt/β-catenin signalling pathway. In this
prospective study, we found that preoperative CRT in rec-
tal cancer significantly increased nuclear β-catenin expres-
sion in tumour cells, conferring a significantly higher risk
of recurrence (p = 0.03) and a trend in poor survival
compared with those who experienced decreased nuclear
β-catenin expression after CRT (p =0.06).
Although RT is a major modality in the treatment of
cancer, little is known about the molecular changes induced
by RT with or without CT. Radiation has been shown to
induce different molecular mechanisms to counteract cell
death, and several preclinical studies have shown that ra-
diation may promote proliferation, migration and tumour
cell invasiveness, which could offset the therapeutic effects
of radiation [9]. β-catenin is controlled by a multi-protein
degradation complex, which contains the tumour suppres-
sor APC, Axin, GSK3β and casein kinase I [2,4]. Mutation
in the multi-protein degradation complex containing APC,
resulting in β-catenin translocation to the nucleus [2,4] has
been identified as one of the most important molecular
events associated with colorectal carcinogenesis. It has been
shown that radiation induces phosphorylation of GSK3β,
an effect known to inhibit GSK3β kinase activity, resultingnuclear β-catenin and E-cadherin expression at diagnosis. A and
ding to stratification on the basis of nuclear β-catenin expression and
Figure 4 Kaplan-Meier estimates of disease-free survival according to increase or decrease of β-catenin and E-cadherin expression after
CRT. A and B. Data on disease-free survival (DFS) for the entire group are shown according to stratification on the basis of the increase or
decrease of nuclear β-catenin and membranous E-cadherin expression after CRT.
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more, a recent preclinical report with a xenograft model
of pancreatic cancer has shown that radiation promotes
the phosphorylation of GSK3β at serine 9. This event
promoted the translocation of β-catenin from the cytosol
to the nucleus, which increased transcriptional activity of
the Wnt/β-catenin pathway, leading to radiation resistance
[10]. Other preclinical investigations have shown that radi-
ation may enrich progenitor cells with an activated Wnt/
β-catenin signalling pathway, which leads to the develop-
ment of radiation resistance in breast cancer cells [14]. Fi-
nally, in head and neck cancer cell lines, radiation has been
shown to induce the translocation of β-catenin to the nu-
cleus, conferring radiation resistance through upregulation
of Ku expression [15]. However, in the clinical setting, there
are no published investigations that link radioresistance





HR (95% CI) HR (95% CI)
Increase in β-catenin
0.06
Decrease vs. increase 0.14 (0.02-0.9) 0.02 0.13 ( 0.01-1.4)
T stage
0.02
T4 vs. T2-T3 1.7 (0.7-4.3) 0.2 4 (1.2-13.4)
N stage
0.6
N- vs. N+ 0.4 (0.18.1.1) 0.07 0.7 (0.2-2.3)
TGR*
0.4
3-5 vs. 1-2 3.6 (1.2-10.7) 0.01 0.5 (0.1-2.6)
pN ††
0.01
pN - vs. pN+ 0.3 (0.14-0.77) 0.007 0.2 (0.06-0.69)
*TGR: Tumor grade regression. pN: pathological lymphatic metastases. †† pN:
pathological lymphatic metastases.Our results have shown that preoperative CRT signifi-
cantly increases nuclear β-catenin expression in tumour
cells, which confers significantly poorer survival com-
pared with those who experienced a decrease in nuclear
β-catenin expression (p = 0.02). This finding almost reached
the cut-off for significance in multivariate analysis (p =
0.06). Moreover, 93% of the patients who presented with
recurrent disease also showed an increase in the expres-
sion of nuclear β-catenin (p = 0.03). On the other hand, pa-
tients who experimented a decrease of nuclear β-catenin
expression after CRT showed an excellent prognosis, with
3 year DFS of 92% vs. 29% (HR 0.17; 95% CI 0.03 to 0.8;
p = 0.02). To the best of our knowledge, this study provides
the first clinical evidence to support the hypothesis that
preoperative CRT in LARC increases nuclear β-catenin
expression in tumour cells, which confers a significantly
higher risk of recurrence and poor survival.
In accordance with other series, our results show that
metastatic recurrence is the main pattern of recurrence for
our patients and isolated locoregional recurrence occurs
rarely after TME plus RT [1]. Nowadays, the leading cause
of treatment failure in LARC treated with preoperative
CRT is metastatic disease [1]. Thus, any improvement
in the survival of these patients will require a better
control of distant disease. The Wnt/β-catenin pathway
stimulates expression of the target genes implicated in
invasion, motility and proliferation [2]. Activation of this
pathway as a result of CRT, with the consequent increase
in the expression of nuclear β-catenin, may be a plausible
mechanism of distant failure. Thus, this prognostic bio-
marker may potentially identify patients with a high risk
of distant recurrence in which new adjuvant therapies
targeting the Wnt/ β-catenin pathway might be investi-
gated. However, this finding must be confirmed prospect-
ively in clinical trials. One recent retrospective clinical
study with 48 patients analysed the expression of β-catenin
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differences were found in nuclear β-catenin expression
before or after CRT [16], although the limited sample
size of this retrospective study may be considered as
biased.
Previous prognostic data on nuclear β-catenin expres-
sion at diagnosis in colorectal cancer have shown conflict-
ing results [7,8]. Our results have shown that patients with
high levels of nuclear β-catenin at diagnosis do not have a
significantly different DFS compared with those with low
nuclear β-catenin expression. Other factors involved in
this complex signalling pathway may play a hidden role
that explains these non-significant differences in prognosis
observed for basal nuclear β-catenin expression. Finally,
β-catenin binds to intracellular E-cadherin and plays a
leading role in cell adhesion and cellular architecture.
Different authors have shown that the absence of mem-
branous E-cadherin is independently associated with a
poor survival rate in colorectal cancer treated with surgery
upfront [17-19]. In contrast, the absence of E-cadherin
was not a significant prognostic factor in our patients.
Our study implies some difficulties that should be
mentioned. Characterising a tumour that has been treated
with CRT is a challenge for several reasons: patients with
TRG1 do not show residual tumour cells after CRT, and
no tumoral tissue is available for the analysis. Furthermore,
in some cases, preoperative CRT leads to histological
changes with no gross tumour visible in the mucosa or
a scarce number of cells that may make analysis difficult
[20]. Moreover, the small size of the endoscopic biopsy
taken in the diagnostic procedure should be considered
as it may not be representative of the tumour studied.
There are also certain difficulties derived from the lack
of standardisation in the evaluation of β-catenin expres-
sion and the heterogeneity that most colorectal cancers
have with respect to the distribution of nuclear β-catenin
expression [21].
These factors render evaluation of the number of cells
that harbour nuclear β-catenin difficult, hindering a
comparison of the pre- and post-treatment expression of
this protein in the same tumour. For all these reasons,
our results should be taken with caution and should be
confirmed with further studies.
However, some strengths of our study include the homo-
geneity of our treatment approach, the prospective design,
and the assessment by two independent pathologists.
Despite the limited sample size, the poor prognostic
value of nuclear β-catenin after CRT reached statistical
significance.
Conclusions
In summary, our study provides the first evidence that
preoperative CRT in LARC patients induces increased
nuclear β-catenin expression in tumour cells and conferspoor survival compared with patients who experience de-
creased nuclear β-catenin expression. Overexpression of
nuclear β-catenin after CRT may help identify a subgroup
of patients in whom adjuvant therapies may be tested for
a better control of systemic disease and an improvement
in survival.
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